Joseph Beaven, MD
Internal Medicine · Charlestown, INNPI 1619963105
Payments from drug & device makers
Across 1,110 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- AbbVie$2K
- GSK$1K
- Takeda Pharmaceuticals U.S.A., Inc.$790
- Pfizer$781
- Amgen$673
- plus $10K from 54 others
What the payments were for
- Food & beverage$18,88899%
- Education$2321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$1,457
- BREZTRI$963
- AIRSUPRA$733
- FASENRA$272
- QELBREE$249
- SYMBICORT$234
- TRELEGY ELLIPTA$227
- Vascepa$216
- VOQUEZNA$125
- BYDUREON$118
- BEVESPI AEROSPHERE$118
- BRILINTA$118
- BREZTRI AEROSPHERE$117
- TRINTELLIX$114
How this compares
$19,120 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 318 | $273,492 |
| RybelsusSemaglutide | 136 | $183,510 |
| EliquisApixaban | 144 | $155,251 |
| OzempicSemaglutide | 125 | $145,176 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 132 | $116,270 |
| JardianceEmpagliflozin | 66 | $89,527 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 103 | $80,300 |
| VascepaIcosapent Ethyl | 93 | $66,871 |
| MounjaroTirzepatide | 62 | $66,552 |
| OtezlaApremilast | 14 | $64,906 |
| VraylarCariprazine Hcl | 34 | $58,444 |
| TrintellixVortioxetine Hydrobromide | 50 | $53,878 |
| Ondansetron Hcl | 243 | $52,962 |
| Nurtec OdtRimegepant Sulfate | 29 | $46,087 |
| Mesalamine ErMesalamine | 118 | $43,131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Airsupra | $3,976 | $372,900445 claims |
| Novo NordiskRybelsus, Ozempic | $348 | $328,686261 claims |
| PfizerEliquis, Nurtec Odt | $781 | $201,338173 claims |
| GSKTrelegy Ellipta | $1,375 | $116,270132 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $662 | $109,15986 claims |
| Lilly USA, LLCMounjaro, Trulicity | $281 | $105,97585 claims |
| AbbVieVraylar, Linzess | $1,796 | $83,11458 claims |
| AmgenOtezla | $673 | $64,90614 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $790 | $53,87850 claims |
| MerckJanuvia, Belsomra | $207 | $43,91649 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $543 | $40,35534 claims |
| NovartisEntresto | $278 | $32,89334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Charlestown
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
- Rita SchmidSouth Bend$599K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.